LGALS3 and metabolic dysfunction-associated steatohepatitis: Interestingly, they all have the inhibition of Galectin 3 as target in two different clinical fibrosis settings, namely non-alcoholic steatohepatitis (NASH) with advance fibrosis [113,114] and idiopathic pulmonary fibrosis (IPS) [115,116].